Centessa Pharmaceuticals PLC ADR (CNTA) - Net Assets
Based on the latest financial reports, Centessa Pharmaceuticals PLC ADR (CNTA) has net assets worth $526.86 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($687.50 Million) and total liabilities ($160.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Centessa Pharmaceuticals PLC ADR (CNTA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $526.86 Million |
| % of Total Assets | 76.64% |
| Annual Growth Rate | 83.78% |
| 5-Year Change | 7.18% |
| 10-Year Change | N/A |
| Growth Volatility | 5878.93 |
Centessa Pharmaceuticals PLC ADR - Net Assets Trend (2019–2025)
This chart illustrates how Centessa Pharmaceuticals PLC ADR's net assets have evolved over time, based on quarterly financial data. Also explore how large is Centessa Pharmaceuticals PLC ADR's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Centessa Pharmaceuticals PLC ADR (2019–2025)
The table below shows the annual net assets of Centessa Pharmaceuticals PLC ADR from 2019 to 2025. For live valuation and market cap data, see CNTA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $526.86 Million | +31.21% |
| 2024-12-31 | $401.55 Million | +69.97% |
| 2023-12-31 | $236.24 Million | -29.72% |
| 2022-12-31 | $336.17 Million | -31.61% |
| 2021-12-31 | $491.55 Million | +15766.82% |
| 2020-12-31 | $3.10 Million | -77.33% |
| 2019-12-31 | $13.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Centessa Pharmaceuticals PLC ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 117372300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $405.00K | 0.08% |
| Other Comprehensive Income | $2.71 Million | 0.52% |
| Other Components | $1.71 Billion | 324.56% |
| Total Equity | $526.86 Million | 100.00% |
Centessa Pharmaceuticals PLC ADR Competitors by Market Cap
The table below lists competitors of Centessa Pharmaceuticals PLC ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Venture Global, Inc.
NYSE:VG
|
$6.10 Billion |
|
MERUS N.V. EO -09
F:2GH
|
$6.11 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
$6.12 Billion |
|
Pegasystems Inc
NASDAQ:PEGA
|
$6.12 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
$6.10 Billion |
|
XTC New Energy Materials Xiamen Co Ltd
SHG:688778
|
$6.10 Billion |
|
Nice Ltd ADR
NASDAQ:NICE
|
$6.10 Billion |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
$6.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Centessa Pharmaceuticals PLC ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 401,545,000 to 526,863,000, a change of 125,318,000 (31.2%).
- Net loss of 197,532,000 reduced equity.
- New share issuances of 275,358,000 increased equity.
- Other comprehensive income decreased equity by 1,499,000.
- Other factors increased equity by 48,991,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-197.53 Million | -37.49% |
| Share Issuances | $275.36 Million | +52.26% |
| Other Comprehensive Income | $-1.50 Million | -0.28% |
| Other Changes | $48.99 Million | +9.3% |
| Total Change | $- | 31.21% |
Book Value vs Market Value Analysis
This analysis compares Centessa Pharmaceuticals PLC ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 307.25x to 10.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.13 | $39.43 | x |
| 2020-12-31 | $0.04 | $39.43 | x |
| 2021-12-31 | $5.46 | $39.43 | x |
| 2022-12-31 | $3.60 | $39.43 | x |
| 2023-12-31 | $2.46 | $39.43 | x |
| 2024-12-31 | $3.51 | $39.43 | x |
| 2025-12-31 | $3.88 | $39.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Centessa Pharmaceuticals PLC ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1316.88%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.30x
- Recent ROE (-37.49%) is above the historical average (-97.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -38.67% | 0.00% | 0.00x | 1.44x | $-6.65 Million |
| 2020 | -344.19% | 0.00% | 0.00x | 3.78x | $-10.97 Million |
| 2021 | -77.69% | 0.00% | 0.00x | 1.28x | $-431.06 Million |
| 2022 | -64.31% | 0.00% | 0.00x | 1.32x | $-249.82 Million |
| 2023 | -63.95% | -2204.65% | 0.02x | 1.52x | $-174.71 Million |
| 2024 | -58.71% | 0.00% | 0.00x | 1.44x | $-275.91 Million |
| 2025 | -37.49% | -1316.88% | 0.02x | 1.30x | $-250.22 Million |
Industry Comparison
This section compares Centessa Pharmaceuticals PLC ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Centessa Pharmaceuticals PLC ADR (CNTA) | $526.86 Million | -38.67% | 0.30x | $6.10 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more